Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
Ann Oncol ; 27(10): 1922-8, 2016 10.
Article in English | MEDLINE | ID: mdl-27502701

ABSTRACT

BACKGROUND: Dynamic contrast-enhanced ultrasonography (DCE-US) has been used for evaluation of tumor response to antiangiogenic treatments. The objective of this study was to assess the link between DCE-US data obtained during the first week of treatment and subsequent tumor progression. PATIENTS AND METHODS: Patients treated with antiangiogenic therapies were included in a multicentric prospective study from 2007 to 2010. DCE-US examinations were available at baseline and at day 7. For each examination, a 3 min perfusion curve was recorded just after injection of a contrast agent. Each perfusion curve was modeled with seven parameters. We analyzed the correlation between criteria measured up to day 7 on freedom from progression (FFP). The impact was assessed globally, according to tumor localization and to type of treatment. RESULTS: The median follow-up was 20 months. The mean transit time (MTT) evaluated at day 7 was the only criterion significantly associated with FFP (P = 0.002). The cut-off point maximizing the difference between FFP curves was 12 s. Patients with at least a 12 s MTT had a better FFP. The results according to tumor type were significantly heterogeneous: the impact of MTT on FFP was more marked for breast cancer (P = 0.004) and for colon cancer (P = 0.025) than for other tumor types. Similarly, the differences in FFP according to MTT at day 7 were marked (P = 0.004) in patients receiving bevacizumab. CONCLUSION: The MTT evaluated with DCE-US at day 7 is significantly correlated to FFP of patients treated with bevacizumab. This criterion might be linked to vascular normalization. AFSSAPS NO: 2007-A00399-44.


Subject(s)
Bevacizumab/administration & dosage , Neoplasms/diagnostic imaging , Neoplasms/drug therapy , Ultrasonography/methods , Adult , Aged , Aged, 80 and over , Angiogenesis Inhibitors/administration & dosage , Biomarkers, Tumor , Contrast Media/administration & dosage , Female , France , Humans , Male , Middle Aged , Neoplasms/pathology
3.
Gastroenterol Clin Biol ; 34(4-5): 314-8, 2010.
Article in English | MEDLINE | ID: mdl-20207091

ABSTRACT

Sorafenib has recently been approved as the gold standard therapy for advanced BCLC-C hepatocellular carcinomas. Although significant improvement of survival rates was shown, objective tumor response rates remained low following RECIST criteria in phases 2 and 3 studies. We report the rare case of a patient with a large hepatocellular carcinoma tumor invading suprahepatic veins in which sorafenib led to a very significant regression by about 90% of the tumor bulk, thus allowing at sterilizing the residual tumor tissue by subsequent combination of transarterial intrahepatic chemoembolization and high dose radiotherapy.


Subject(s)
Antineoplastic Agents/therapeutic use , Benzenesulfonates/therapeutic use , Carcinoma, Hepatocellular/therapy , Liver Neoplasms/therapy , Pyridines/therapeutic use , Carcinoma, Hepatocellular/pathology , Chemoembolization, Therapeutic , Combined Modality Therapy , Humans , Liver Neoplasms/pathology , Male , Middle Aged , Niacinamide/analogs & derivatives , Phenylurea Compounds , Radiotherapy Dosage , Radiotherapy, Conformal , Sorafenib , alpha-Fetoproteins/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...